NEW YORK, April 24, 2015 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID) (part of the National Institutes of Health [NIH]) provided grants totaling more than $11 million to nine research projects for the development of diagnostic tests for antibiotic-resistant bacteria. In light of recent HAI outbreaks at U.S. health facilities, the NIAID and other government authorities are supporting research into rapid, multiplexed and effective tests using alternative methods to traditional culturing. Kalorama reviewed NIAID grant recipients with notable test platforms, including commercialized rapid molecular platforms and innovative research and noted the number of grants were for carbapenem-resistant Enterobacteriaceae (CRE), bloodstream infection, and urinary tract infection testing. Kalorama Information offers market research reports relevant to HAI testing including The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment.
Commonly referred to as bacterial identification and antibiotic susceptibility testing (ID/AST), the traditional test format uses culture media to identify (ID) pathogens through substrate reactions indicative of metabolism or enzymatic activity specific to the species or strain. Panels or other specialized cultures are then used to determine the resistance or susceptibility to applied antibiotics through the observation of cultured growth or lack of growth.
"The critical nature of drug-resistance hospital-acquired infections (HAIs) has pressured ID/AST testing times;" said Emil Salazar, analyst for Kalorama information in a recent blog post. "Timely results are need to implement alternative treatments for infected patients before the spread of infection to the bloodstream or the possible onset of sepsis."
Grant recipients include.
- BioFire Diagnostics. The bioMérieux subsidiary offers a powerful, leading near-patient or point-of-care (POC) infectious molecular test platform, the FilmArray. The product is already used among hospitals with an FDA-cleared Blood Culture Identification (BCID) panel able to identify numerous HAI pathogens as well as the antibiotic resistance genes mecA (methicillin), vanA/B (vancomycin) and KPC (carpagenem).
- With clinical partner the Denver Health and Hospital Authority, Accelerate Diagnostics will look to field test its imaging-based Accelerate ID/AST system. The system bypasses culturing and nucleic acid amplification procedures to provide pathogen identification in one hour and AST results in 3 hours. The cell imaging platform extracts bacterial cells from patient blood and micropipettes them in up to 48 cassette-held flowcell channels.
- First Light Biosciences has applied its no-magnification cell imaging system to urinary tract infection (UTI) testing. . The MultiPath UTI ID test will quantitatively detect 9 of the most common UTI pathogens in as little as 15 minutes. Pathogen detection is followed by an AST test with results provided in 3 hours.
- A research collaboration including Johns Hopkins University, Stanford University, the University of Arizona and General Electric (GE) Global Research also seeks to bypass amplification in molecular testing for HAIs. The novel molecular approach uses microfluidics to produce millions of picoliter-sized droplets able to encapsulate individual bacterial cell and probe or cell and antibiotic mixtures for ID and AST testing.
The above projects all seek to shorten time to results using alternatives to culturing, including no-amplification molecular probe hybridization or detection without prior culturing. As demonstrated by public involvement, ID/AST testing at health facilities is critical not only to individual patient treatment, but initiated an effective institutional response to HAI contamination. Concerns over pathogen drug resistance has already delivered a significant hospital molecular diagnostics market, and outstanding demand for faster HAI test results is likely to bring further diagnostics investment outside of central labs.
Kalorama Information offers The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment. This report considers all the market opportunities for companies with solutions for HAIs, including the device sterilization, facility cleaning, treatment and HAI testing markets. To purchase the report or for more information please visit: http://www.kaloramainformation.com/redirect.asp?progid=87364&productid=7719426.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article